🇺🇸 FDA
Patent

US 11623010

Pharmaceutical carrier in the preparation of an anti-diabetic pharmaceutical composition and methods for treatment

granted A61KA61K31/4375A61K31/56

Quick answer

US patent 11623010 (Pharmaceutical carrier in the preparation of an anti-diabetic pharmaceutical composition and methods for treatment) held by BEIJING RONGXIANG INSTITUTE OF REGENERATIVE MEDICINE CO., LTD. expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BEIJING RONGXIANG INSTITUTE OF REGENERATIVE MEDICINE CO., LTD.
Grant date
Tue Apr 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K31/4375, A61K31/56, A61K31/575, A61K47/44